SuperworthStereotaxis profit margin STXS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −74.2%
- Operating margin, 12 months
- −75.7%
- Net margin on a year earlier
- −0.8 pts
- Peer median
- 6.8%
Over the twelve months to Jun 30, 2026, Stereotaxis kept −74.2% of its revenue as net profit, with an operating margin of −75.7% and a gross margin of 55.6%.
Five years earlier its net margin was −16.6%.
The median for 10 healthcare stocks of a similar size is 6.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −66.8% | −68.3% | 52.7% |
| FY2024 | −89.3% | −91.9% | 54.2% |
| FY2023 | −77.4% | −81.6% | 55.5% |
| FY2022 | −65.0% | −66.7% | 65.6% |
| FY2021 | −30.6% | −36.8% | 66.3% |
| FY2020 | −25.0% | −25.2% | 71.2% |
| FY2019 | −15.9% | −16.7% | 78.8% |
| FY2018 | 0.4% | −8.4% | 80.5% |
| FY2017 | −18.9% | −19.0% | 65.5% |
| FY2016 | −16.4% | −20.0% | 76.6% |
| FY2015 | −19.5% | −14.4% | 72.3% |
| FY2014 | −14.9% | −15.4% | 76.5% |
| FY2013 | n/a | −23.2% | 71.1% |
| FY2012 | −19.8% | −22.8% | 68.3% |
| FY2011 | −76.3% | −76.1% | 70.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −74.2% | −0.8 pts | −75.7% | |
| Q1 FY26 | −69.5% | +22.7 pts | −71.0% | |
| Q4 FY25 | −66.8% | +22.5 pts | −68.3% | |
| Q3 FY25 | −78.6% | +7.2 pts | −80.1% | |
| Q2 FY25 | −73.4% | +14.0 pts | −75.1% | |
| Q1 FY25 | −92.2% | −18.9 pts | −94.2% | |
| Q4 FY24 | −89.3% | −12.0 pts | −91.9% | |
| Q3 FY24 | −85.8% | −18.6 pts | −89.2% | |
| Q2 FY24 | −87.4% | −21.4 pts | −91.4% | |
| Q1 FY24 | −73.3% | −2.6 pts | −77.4% | |
| Q4 FY23 | −77.4% | −12.4 pts | −81.6% | |
| Q3 FY23 | −67.2% | −7.1 pts | −71.1% |
Against its peers
Companies in Healthcare nearest Stereotaxis' size, closest first, today.
| Company | Profit margin |
|---|---|
| STXSStereotaxis | −74.2% |
| KEQUKewaunee Scientific | 3.0% |
| ICCCImmucell | 2.6% |
| LFVNLifevantage | 2.8% |
| SPROSpero Therapeutics | 15.7% |
| APTAlpha Pro Tech | 6.8% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| ATNMActinium Pharmaceuticals | n/m |
| ELMDElectromed | 15.3% |
| Peer median | 6.8% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Stereotaxis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.